United States. Securities and Exchange Commission

Stock exchanges

Prothena Corporation Announces Significant Workforce Reduction and Substantial Operating Cost Reduction

Prothena Corporation Public Limited Company, a multinational biotechnology company, has announced an approximate 63% reduction in its workforce in order to substantially reduce its operating costs to those necessary to support its remaining wholly-owned programs, its obligations to partnered programs, and its anticipated business development activities. This decision follows the

Stock exchanges

Immuneering Corporation Announces Interim Data from Phase 2a Clinical Trial of Atebimetinib in Pancreatic Cancer Patients

Immuneering Corporation, a biotechnology company, has announced interim data from its ongoing Phase 2a clinical trial evaluating atebimetinib, a once-daily oral MEK inhibitor, in combination with modified Gemcitabine/nab-Paclitaxel (mGnP) in first-line pancreatic cancer patients. As of May 26, 2025, of the 36 response evaluable patients in the mGnP arm,